US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Women's Health: market research reports

Women’s health is a perspective of prevention and treatment that looks at health concerns unique to females. Even though slightly more than half of the US population is female, medical research historically has neglected the health needs of women, other than reproductive issues. Recently there have been major changes in government and private support of women’s health research -- in policies, regulations, and the organization of research efforts.
In a recent Institute of Medicine (IOM) report, the Washington DC-based institute found that women’s health research has contributed to significant progress over the past 20 years in lessening the burden of disease and reducing deaths from some conditions for women, while other conditions have seen only moderate change or even little or no change. Gaps remain, both in research areas and in the application of results to benefit women in general and across multiple population groups.

Viewing women’s health exclusively as a function of sex differences is too narrow, according to the IOM report. It frames women’s health and well-being as a function only of biological factors and how they differ in men and women, and ignores the role of gender, which is affected by broader social and community factors. The IOM finds that there has been inadequate attention paid to the social and environmental factors that, along with biologic risk factors, influence women’s health. Although progress has been made in identifying behavioral determinants of women’s health, such as smoking, diet, and physical activity, few studies have tested ways to modify these determinants in women or examined the effects of social and community factors in specific groups of women. To advance this area of research, the IOM recommends that the National Institutes of Health (NIH) support research on common determinants and risk factors that underlie multiple diseases.

Significant progress has been made in reducing mortality for women from breast cancer, cardiovascular disease and cervical cancer. This can be attributed in part to increased consumer demand and awareness, which has resulted in additional funding and research; improved diagnosis; screening and treatment; and, in the case of cervical cancer, a vaccine.

RSS Feeds

Women's Health market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Cervical Cancer Test Market & Patients - Pap Smear, HPV DNA, VIA – Test & Patients – Worldwide
4/1/2014 | published by: Renub Research
... over the world. However in the past few decades, mortality from cervical cancer has significantly decreased in developed countries due to widely use of Pap smear test. HPV DNA and VIA test are other popular ...  |  read more...
$1,490.00
Metastatic Breast Cancer Global Clinical Trials Review, H1, 2014
3/31/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Metastatic Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
$2,500.00
Menopausal Hot Flashes - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... information on the therapeutic development for Menopausal Hot Flashes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
$2,000.00
Female Sexual Dysfunction - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
$2,000.00
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
$2,000.00
Breast Cancer Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of breast cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 290 drug targets that are included in this drug-pathway analyzing ...  |  read more...
$5,622.50
Ovarian Cancer Drug Pathway Analyzer 2014
3/25/2014 | published by: BioSeeker Group AB
... intracellular signaling pathways for the treatment of ovarian cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 240 drug targets that are included in this drug-pathway analyzing ...  |  read more...
$5,622.50
Analytical Tool - Breast Cancer
3/25/2014 | published by: BioSeeker Group AB
... at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the ...  |  read more...
$11,625.00
Breast Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... and metastatic setting, the overall survival remains below five years. There are today 383 companies plus partners developing 528 drugs targeting breast cancer in development. In addition, there are 8 suspended drugs and the accumulated ...  |  read more...
$5,622.50
Ovarian Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... an important secondary indication for existing and pipeline drugs. There are today 242 companies plus partners developing 335 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number ...  |  read more...
$5,622.50
Hormone Sensitive Breast Cancer Global Clinical Trials Review, H1, 2014
3/19/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Sensitive Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
$2,500.00
Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014
3/19/2014 | published by: GlobalData
... trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory Breast Cancer. It includes an overview of the trial numbers and their recruitment status as per the site ...  |  read more...
$2,500.00
United States Mammography Equipment Market Outlook to 2020
3/7/2014 | published by: GlobalData
... value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories – Film-Screen Mammography Equipment and Full-Field Digital Mammography Equipment (2D Digital Mammography Equipment and 3D ...  |  read more...
$2,500.00
Women Infertility - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
$2,000.00
Vulvovaginal Candidiasis - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
$2,000.00
Cervical Cancer - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
$2,000.00
Fallopian Tube Cancer - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest ...  |  read more...
$2,000.00
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
$2,000.00
Endometrial Cancer - Pipeline Review, H1 2014
2/28/2014 | published by: Global Markets Direct
... therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
$2,000.00
Breast Cancer: New targeted therapies transform treatment - KOL Insight
2/10/2014 | published by: FirstWord
... patients. Now the sector is set for further positive change and expansion as next generation products for HER2-positive disease come to market, and CDK4/6 and P13K inhibitors hold the prospect of new treatments for hormone ...  |  read more...
$4,995.00
Human Papilloma Virus Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... in human papilloma virus partnering deals Top human papilloma virus deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The Human Papilloma Virus Partnering 2009-2014 provides understanding and access ...  |  read more...
$995.00
Sexual Dysfunction Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... partnering deals Top sexual dysfunction deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The Sexual Dysfunction Partnering 2009-2014 provides understanding and access to the sexual dysfunction partnering deals ...  |  read more...
$995.00
Ovarian Cancer Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... of ovarian cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ovarian cancer technology. These deals tend to ...  |  read more...
$995.00
Infertility Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The Infertility Partnering 2009-2014 provides understanding and access to the infertility partnering deals and agreements entered into by the worlds ...  |  read more...
$995.00
Breast Cancer Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... of breast cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors breast cancer technology. These deals tend to ...  |  read more...
$1,795.00
< prev 1    3  4  5  6  7  8  9  10  
 
Our Clients